Biologics company WuXi Biologics said on Monday that WuXi Vaccines has entered into a Letter of Intent (LOI) for a strategic 20-year,USD3bn manufacturing and supply partnership with a global vaccine company.
The LOI allows WuXi Vaccines to build an integrated vaccine manufacturing facility, including drug substance manufacturing (DS), drug product manufacturing (DP) as well as Quality Control labs (QC).
Upon completion, the new facility will manufacture 100% of the global market of one of WuXi Biologics' partner's vaccine products.
WuXi Vaccines, which builds world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines, is a joint venture company between Shanghai based Hile Bio-Technology (stock code 603718.SH) and WuXi Biologics (2269.HK), an open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma